Setterwalls has advised Qlife Holding AB (”Qlife”) in connection with the listing on Nasdaq First North Growth Market. The trading in Qlife’s shares and warrants commenced on 2 March 2020.
Qlife develops an innovative medtech device, aiming to provide people with access to safe and validated biomarkers in their homes. The users of the device will be able to test their blood more frequently, and hence gain increased insights of their health, as well as being able to detect diseases at an earlier stage. Qlife’s technical platform, Egoo, consists of a measuring instrument, a digital software infrastructure and disposable capsules, where each capsule contains a test for a specific biomarker which can be tested with a blood sample.
In connection with the listing, an offer of units was made to the general public and institutional investors in Sweden and abroad, whereby Qlife received issue proceeds of approximately SEK 50.5 million in cash before issue costs (including fully exercised over-allotment option). In addition, Qlife may receive additional issue proceeds of a maximum of approximately SEK 39.1 million before issue costs, provided that all warrants issued in connection with the offer are exercised for subscription of new shares in Qlife. Setterwalls acted as legal advisor to Qlife in the listing process.